scholarly journals FECAL MICROBIOTA TRANSPLANTATION: FAST PARASITES DIAGNOSIS BY MULTIPLEX PCR

2021 ◽  
Vol 9 (1) ◽  
Author(s):  
Omar Mura ◽  
Elisa Gamalero ◽  
Luigi Di Matteo ◽  
Andrea Rocchetti
Keyword(s):  
Light Microscopy ◽  
Multiplex Pcr ◽  
Microscopic Examination ◽  
Gold Standard ◽  
Fecal Microbiota Transplantation ◽  
Intestinal Parasites ◽  
Fecal Microbiota ◽  
Analytical Performance ◽  
Preliminary Evaluation ◽  
Faecal Microbiota

Objectives: Evaluation of the analytical performance of the Novodiag  Stool Parasites biomolecular assay for the detection of intestinal parasites in faeces of the faecal microbiota transplant donor. Methodology: Comparison between the gold standard for the diagnosis of intestinal parasites, light microscopy, and the Novodiag  Stool Parasites biomolecular assay through the use of 22 fecal samples. Results: Twelve out of 22 samples were positive on microscopic examination. In order to assess the overlapping between the results obtained through parasitological examination and the molecular methodology, all samples were tested to the Novodiag  Stool Parasites assay. Positive samples detected by biomolecular assay were 11 out of 22. Conclusion: The preliminary evaluation of the analytical performance of the Novodiag  Stool Parasites kit can be considered promising. The Novodiag  Stool Parasites kit can be effectively used as a tool in the fast diagnosis of intestinal parasitoses on the faecal microbiota transplant donor faeces.

scholarly journals Effects of different treatment of faecal microbiota transplantation techniques on ulcerative colitis in rats

2021 ◽  
Author(s):  
Fangyuan Zhu ◽  
Yifan Ke ◽  
Yiting Luo ◽  
Jiaqian Wu ◽  
Pei Wu ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Fecal Microbiota Transplantation ◽  
Bacterial Flora ◽  
Intestinal Flora ◽  
Clinical Manifestations ◽  
Fecal Microbiota ◽  
Control Group ◽  
Faecal Microbiota ◽  
Faecal Microbiota Transplantation ◽  
Model Control

Abstract Background: Ulcerative colitis (UC) is a chronic non-specific inflammatory bowel disease with abdominal pain, mucus, pus, and blood in the stool as the main clinical manifestations. The pathogenesis of UC is still not completely clear, and multiple factors such as genetic susceptibility, immune response, intestinal microecological changes, and environmental factors together lead to the onset of UC. In recent years, the role of intestinal flora disturbance on the pathogenesis of UC has received widespread attention. Therefore, fecal microbiota transplantation(FMT), which changes the intestinal microecological environment of UC patients by transplantation of normal fecal bacteria, has attracted increasing attention from researchers. However, there are no guidelines at home and abroad to recommend fresh FMT or frozen FMT in the treatment of UC, and there are a few studies on this. Therefore the purpose of this experiment was to explore the effects of fresh and frozen fecal microbiota transplantation methods on the treatment of experimental ulcerative colitis models in rats.Results: Compared with the model control group, all faecal microbiota transplantation groups achieved better efficacy, mainly manifested as weight gain by the rats, improvements in faecal characteristics and blood stools, reduced inflammatory factors, and normal bacterial flora. The efficacy of the frozen faecal microbiota transplantation group was better than that of the fresh faecal microbiota transplantation group in terms of behaviour and colon length .Conclusions: FMT is a feasible method for treating UC. The mechanism of action may be via competitive inhibition of pathogenic microorganisms, improved immune metabolism, and reduced inflammatory response to mitigate the damage to the intestinal barrier and cause UC remission. Compared with fresh FMT, the therapeutic effect of frozen FMT may be greater.

scholarly journals Fecal microbiota transplantation for graft-versus-host disease in children and adults: methods, clinical effects, safety

2020 ◽  
Vol 92 (7) ◽  
pp. 43-54
Author(s):  
O. V. Goloshchapov ◽  
A. B. Chukhlovin ◽  
E. A. Bakin ◽  
O. V. Stanevich ◽  
R. V. Klementeva ◽  
...  
Keyword(s):  
Placebo Group ◽  
Adverse Events ◽  
Multiplex Pcr ◽  
Clinical Efficacy ◽  
Graft Versus Host Disease ◽  
Fecal Microbiota Transplantation ◽  
Complete Response ◽  
Fecal Microbiota ◽  
Graft Versus Host ◽  
Bacterial Mass

Aim.Was to evaluate clinical efficacy, adverse events and changes in the gut microbiome after fecal microbiota transplantation (FMT) in patients with gastrointestinal (GI) form of graft-versus-host disease (GVHD). Materials and methods.The prospective single-center study in R.M. Gorbacheva institute included 27 patients with GI GVHD after allogeneic stem cell transplantation. 19 patients received FMT, 8 patients received placebo. Clinical scales for GI autoimmune diseases were used to evaluate response. Microbiome alterations were assessed with multiplex PCR. Results.After FMT higher overall bacterial mass (р=0.00088), higher bacterial numbers ofBifidobacteriumspp. (р=0.021),Escherichia coli(р=0.049) andBacteroides fragilisgr. (р=0.000043) compared to placebo group. Also higher bacterial mass was observed in patients with clinical response (р=0.0057). The bacterial mass after procedure in non-responders was compared to the placebo group (р=0.31). Partial response of GVHD was achieved faster in the FMT group compared to placebo (median 4 days vs 48 days,p=0.014). Complete response was observed in 8 (42%), 14 (74%) and 16 (84%) at 30, 60 and 90 days respectively, while in the placebo group only 0%, 1 (13%) and 4 (50%) achieved complete response at the same time points. The incidence and severity of adverse events was comparable between FMT and the placebo group. Conclusion.FMT in patients with refractory GI GVHD was associated with favorable clinical outcomes and recovery in certain marker bacterial populations. Multiplex PCR can be used to assess an engraftment of a donor microbiota. FMT in GI GVHD was not associated with life-threatening adverse events, but further studies are required to validate clinical efficacy.

Sign in / Sign up

Export Citation Format

Share Document